Fighting Alzheimer’s With New Drug Compound

Background

  • The tau protein allows the nervous system to operate normally.
  • Alzheimer’s disease is rooted in degeneration of neurons to the brain.
  • For some, toxic ‘tangles’ accumulate in the tau protein, and the brain loses synapses. This causes memory disorders to occur.

Via Washington University School Of Medicine

An encouraging article published by Tamara Bhandari details a synthetic molecule tested on mice and monkeys that fights against toxic tau proteins.

The findings suggest that the molecule – known as an antisense oligonucleotide – potentially could treat neurodegenerative diseases characterized by abnormal tau, including Alzheimer’s.

“We’ve shown that this molecule lowers levels of the tau protein, preventing and, in some cases, reversing the neurological damage,” said Timothy Miller, MD, PhD, the David Clayson Professor of Neurology and the study’s senior author. “This compound is the first that has been shown to reverse tau-related damage to the brain that also has the potential to be used as a therapeutic in people.”

Via St. Louis Business Journal

We first learned of this story through Diana Barr’s article in the St. Louis Business Journal’s Health Care section. Brooking Park anxiously awaits more details. Barr concludes,  “Human trials of oligonucleotides are underway for several other neurological diseases.”

Thank You, Washington University

On behalf of all the loved ones suffering from a devasting neurological disease worldwide, in the St. Andrew’s Network, or here at home at Brooking Park, we send our full support and gratitude for your research.

Brooking Park has been linked to Wash U in the past. Recently, the newly-developed Come Sing With Us program sang for the Brooking Park Memory Care unit. We’ve also been involved directly with School Of Medicine research through their KARE program.

Leave a Reply

Your email address will not be published. Required fields are marked *